Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


  
 
  
Reply to this topic

RCE, RECCE PHARMACEUTICALS LTD
macdtrader
post Posted: Jul 9 2020, 08:13 PM
  Quote Post


Posts: 90
Thanks: 9


In Reply To: nipper's post @ Jul 9 2020, 07:48 PM

Spectacular performer

 
nipper
post Posted: Jul 9 2020, 07:48 PM
  Quote Post


Posts: 7,122
Thanks: 2446


some boost in these Covid times. What it means is almost unimportant; they are throwing everything t the problem.
QUOTE
RECCE Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program
Highlights:

RECCE 327 and New RECCE 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively)
Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute
Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections

Priority 1 status is defined as highest or strong likelihood of antiviral or antiseptic efficacy Compounds in this grouping will be eligible for stage 1 laboratory screening trials.
and

QUOTE
Recce chairman John Prendergast said under the agreement, the company would retain all intellectual property rights. He added that Recce would fund the first stage of the program's development, which is expected to cost $35,000.

Dr Prendergast said if testing progresses, costs will increase at each stage.
The company will make (an) announcement in relation to progress to any further stage, and will detail any material associated costs. We are very pleased to have been selected by the CSIRO, one of the largest and most diverse scientific research organisations in the world, to investigate the efficacy of two of our promising compounds against SARS-CoV-2. The compounds' unique, universal mechanisms of action indicate the potential to attack a broad range of viruses and as well, overcome the threat of viruses' typical hyper-mutation into new and deadly pathogens.
It comes after CSIRO researchers last week found that lab-grown cells from the upper layer of the airway to the lungs the human bronchial epithelium reliably mimic a live person's airway's response to viruses. CSIRO research scientist Elizabeth Pharo said the airway model could potentially be used to screen up to 100 antiviral compounds within three months, and CSIRO is exploring ways to further accelerate screening including the use of robotic technology.
For many respiratory diseases, such as COVID-19, the airways act as the first responders to inhaled pathogens. When we infected our airway epithelial cultures with the 2009 pandemic H1N1 influenza virus, the cells had the same innate immune response as in a live person's airway. It is hoped this work will help improve our understanding of how COVID-19 may affect people with pre-existing lung conditions... said Dr Pharo

up 50% today to over $1.00. Was 30c a share in April



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Nov 28 2019, 05:39 PM
  Quote Post


Posts: 7,122
Thanks: 2446


QUOTE
...ended the quarter with cash of $454,388 prior to the equity placement of $6,768,444 (before costs), post quarter end on 10 October 2019. On 18 September the business received further funds from the Australian Governmentunder the Australian R&D incentive scheme. The business is well funded to progress its commercial and clinical milestones.

Operational Highlights
We continue to receive good results from our manufacturing in preparation for pending human clinical studies. During the quarter we received a positive response from the US Food and Drug Administration relating to a five-fold increase in scaled manufacture of RECCE 327® and drug quality following submission of a Chemistry, Manufacturing and Controls (CMC) data pack as part of the investigational drug application process.

A leading international clinical trial logistics group was contracted to handle dispatch and delivery of RECCE® 327 globally, according to FDA requirements.

International Interest Growing – The Company was invited to give the opening R&D address at the World Antimicrobial Resistance Congress in the US on 7 November




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
macdtrader
post Posted: Nov 6 2019, 08:38 PM
  Quote Post


Posts: 90
Thanks: 9


In Reply To: macdtrader's post @ Nov 5 2019, 01:21 PM

Behaving beautifully.
Limited supply. Low volume retrace into previous resistance at 28.5.
I don't imagine this will sit sub 30c for long. Perhaps hours. A few days at worst before launch.
FDA stamp? Pack your xmas stocking full.

 
macdtrader
post Posted: Nov 5 2019, 01:21 PM
  Quote Post


Posts: 90
Thanks: 9


In Reply To: strayinvestor's post @ Oct 28 2019, 10:49 PM

Starting to take shape.
Im john holmes on this.
FDA approval and this will multi bag imho.
That's what Im holding and praying for.
Could be a ripper xmas earner.

 
strayinvestor
post Posted: Oct 28 2019, 10:49 PM
  Quote Post


Posts: 2


In Reply To: macdtrader's post @ Oct 28 2019, 07:19 PM

The biggest uncertainty is that it is still pre clinical .

 

Featured Stock Stories





macdtrader
post Posted: Oct 28 2019, 07:19 PM
  Quote Post


Posts: 90
Thanks: 9


In Reply To: strayinvestor's post @ Oct 26 2019, 09:05 AM

That's a big positive but I want to hear some negatives on this stock.

 
strayinvestor
post Posted: Oct 26 2019, 09:05 AM
  Quote Post


Posts: 2


In Reply To: macdtrader's post @ Oct 25 2019, 10:43 PM

I like that it has FDA QIDP designation which gives the company fast track regulatory review plus 10 years of market exclusivity.

 
macdtrader
post Posted: Oct 25 2019, 10:43 PM
  Quote Post


Posts: 90
Thanks: 9


In Reply To: macdtrader's post @ Oct 25 2019, 09:08 PM

Recce also to give the opening address at the at 2019 World Antibiotic Resistance Congress.
600 attendees from 40 countries.
I've taken a small starter position with the intention to get heavy before the meeting.
I'm looking for feedback as to why I shouldn't.


 
macdtrader
post Posted: Oct 25 2019, 09:08 PM
  Quote Post


Posts: 90
Thanks: 9


Can we get a ticker for RCE?
And has anyone got any views on this company?
Looks solid fundamentally and technically but biotechs not my forte.
From what I can see FDA approval would give the stock a big bump.

 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING